Last reviewed · How we verify
IBI3003
At a glance
| Generic name | IBI3003 |
|---|---|
| Sponsor | Fortvita Biologics (USA)Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma (PHASE1, PHASE2)
- A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IBI3003 CI brief — competitive landscape report
- IBI3003 updates RSS · CI watch RSS
- Fortvita Biologics (USA)Inc. portfolio CI